Access
To read this story in full you will need to login or make a payment (see right).
Commentary
Nature Medicine 13, 290 - 294 (2007)
doi:10.1038/nm0307-290
Challenges in tuberculosis drug research and development
Ann M Ginsberg1 & Melvin Spigelman1
- The authors are at the Global Alliance for TB Drug Development, New York, New York, USA. e-mail: ann.ginsberg@tballiance.org
The present decade has seen a reawakening of tuberculosis (TB) drug research and development (R&D), spurred on by an urgent need to stem the tide of the disease globally and develop new, more effective treatments against drug-sensitive and resistant strains. As a result, there are now seven products in clinical development and the largest pipeline of early-stage projects and compounds in history.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mycobacterium tuberculosis virulence: lipids inside and outNature Medicine News and Views (01 Mar 2007)
Mycobacterium tuberculosis virulence: lipids inside and outNature Medicine News and Views (01 Mar 2007)
See all 9 matches for News And Views